AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15156251
Drug: Topical Aescin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Aescin + essential phospholipids (AEPL) gel applied for 2 weeks, three times daily
Trial: 2060547
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg o.d.
Trial: 30715153
Drug: Pembrolizumab 2
RxNorm normalized name: pembrolizumab 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks until disease progression, intolerable toxicity, or patient/investigator decision to withdraw
Trial: 29378603
Drug: Chemotherapy following
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy following ESD
Trial: 20627022
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil 1 mg/kg intravenous 15 minutes before induction of general anesthesia (Group B)
Trial: 18343243
Drug: MLR methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLR methylphenidate 20 mg QD
Trial: 18343243
Drug: OROS methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OROS methylphenidate 18 mg QD
Trial: 15841929
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 100 microg every 2 hours
Trial: 15841929
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol 100 microg every 2 hours
Trial: 12109627
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of oral 17beta E2 daily (group A)
Trial: 12109627
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg E2 daily plus 5 mg daily oral dydrogesterone (group B)
Trial: 12109627
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg E2 and 10 mg dydrogesterone (group C)
Trial: 10674879
Drug: CEF (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF (cyclophosphamide 100 mg m(‐2) p.o. days 1‐14, fluorouracil 500 mg m(‐2) i.v. days 1 and 8, epirubicin 30 mg m(‐2) i.v. days 1 and 8)
Trial: 10674879
Drug: CNF (cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNF (cyclophosphamide 100 mg m(‐2) p.o. days 1‐14, fluorouracil 500 mg m(‐2) i.v. days 1 and 8, mitoxantrone 6 mg m(‐2) i.v. days 1 and 8)
Trial: 9499814
Drug: Histamine challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine challenge after beta 2‐agonist pre‐treatment
Trial: 26687984
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy without exercise training (Control)
Trial: 22706204
Drug: Fluoride concentration
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride concentration at 20 mg/l
Trial: 22706204
Drug: Fluoride concentration
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride concentration at 10 mg/l
Trial: 22706204
Drug: Fluoride concentration
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride concentration at 5 mg/l
Trial: 22706204
Drug: Fluoride concentration
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride concentration at 2.5 mg/l
Trial: 22706204
Drug: Fluoride concentration
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride concentration at 0 mg/l
Trial: 22706204
Drug: Enamel fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel fluoride uptake (EFU) at 20 mg/l
Trial: 22706204
Drug: Enamel fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel fluoride uptake (EFU) at 10 mg/l
Trial: 22706204
Drug: Enamel fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel fluoride uptake (EFU) at 5 mg/l
Trial: 22706204
Drug: Enamel fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel fluoride uptake (EFU) at 2.5 mg/l
Trial: 22706204
Drug: Enamel fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel fluoride uptake (EFU) at 0 mg/l
Trial: 16988647
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g xylitol in water
Trial: 16988647
Drug: 35 g
RxNorm normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 g xylitol in water
Trial: 16988647
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g erythritol in water
Trial: 16988647
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g erythritol in water
Trial: 16988647
Drug: 35 g
RxNorm normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 g erythritol in water
Trial: 16988647
Drug: 45 g
RxNorm normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 g sucrose
Trial: 18003959
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 microg once daily)
Trial: 15286097
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg as a single oral dose
Trial: 15286097
Drug: Ximelagatran 36
RxNorm normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran 36 mg twice daily for 5 days plus a 40 mg oral dose of atorvastatin on day 4
Trial: 9069575
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg i.v. ondansetron
Trial: 8260695
Drug: EVDAC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVDAC regimen (high-dose epirubicin, vincristine, dexamethasone, followed by cyclophosphamide and high-dose cytarabine)
Trial: 995040
Drug: Mazindol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazindol (2 mg one hour before lunch)
Trial: 26031908
Drug: Bifidobacterium animalis
RxNorm normalized name: Bifidobacterium Animalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium animalis subsp. lactis (BB‐12(®)) at a dose of 10(9) CFU
Trial: 24923723
Drug: 1 week
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 week hemifield eye patching and daily sessions of optokinetic stimulation (n=11)
Trial: 24923723
Drug: No neglect-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No neglect-specific treatment (n=10)
Trial: 22722637
Drug: Herbal Fufang
RxNorm normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal Fufang (10 g/day, twice per day, n = 101)
Trial: 20842051
Drug: CpG loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CpG loaded virus-like nanoparticles vaccine
Trial: 15112937
Drug: Antiepileptic medications
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic medications
Trial: 17508528
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (normal neurologic examination, normal test results, no structural brain disease)
Trial: 2378793
Drug: Loxiglumide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (2.5 mg kg‐1 in 10 min, followed by 5 mg kg‐1 h‐1 for 200 min)
Trial: 141634
Drug: Danazol 50
RxNorm normalized name: danazol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol 50 mg daily
Trial: 141634
Drug: Danazol 100
RxNorm normalized name: danazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol 100 mg daily
Trial: 31735553
Drug: Cytomegalovirus gB-MF59
RxNorm normalized name: Cytomegalovirus immunoglobulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytomegalovirus gB-MF59 vaccine
Trial: 30095776
Drug: 20‐mL buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20‐mL buffered 1% lidocaine paracervical block
Trial: 15766446
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa inhibitors administration
Trial: 15766446
Drug: Beta-blockers administration
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers administration
Trial: 15766446
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors administration
Trial: 15766446
Drug: Statins administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins administration
Trial: 9026373
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg Tianeptine (TIA)
Trial: 9026373
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg Tianeptine (TIA)
Trial: 9026373
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Fluvoxamine (FLU)
Trial: 29030268
Drug: Topical vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical vancomycin plus standard of care
Trial: 21569111
Drug: 1550-nm non-ablative
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1550-nm non-ablative fractional photothermolysis (NFP) treatment; 4 sessions at 3-week intervals, energy: 15 mJ/MTZ, total density: 1048 MTZs/cm², density per pass: 131 MTZs/cm², total coverage: 20%
Trial: 21569111
Drug: 1550-nm non-ablative
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1550-nm non-ablative fractional photothermolysis (NFP) treatment
Trial: 16876301
Drug: Dopaminergic agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopaminergic agonist (piribedil 50 mg/day)
Trial: 15765306
Drug: Quadruple-drug regimen:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple-drug regimen: zidovudine/lamivudine/abacavir/nevirapine
Trial: 22414635
Drug: Endotoxin administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endotoxin administration (0.8 ng/kg)
Trial: 9836029
Drug: Morphine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (2 mg loading dose, 1 mg in 4 ml bupivacaine 0.125%)
Trial: 9836029
Drug: Fentanyl (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (50 micrograms loading dose, 20 micrograms in 4 ml bupivacaine 0.125%)
Trial: 3051044
Drug: 2 'Franol'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 'Franol' tablets
Trial: 3051044
Drug: 1 'Franol'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 'Franol' tablet
Trial: 3051044
Drug: 2 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 placebo tablets
Trial: 26525410
Drug: WATI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WATI with messaging further enhanced with personal secure messaging with a tobacco treatment specialist and an online support group (personalized)
Trial: 24187859
Drug: Low-dose Huadananshen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Huadananshen mistura (10 mL/day)
Trial: 24187859
Drug: High-dose Huadananshen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Huadananshen mistura (20 mL/day)
Trial: 15531677
Drug: Triple-fortified salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-fortified salt (TFS) with 30 mug I, 2 mg Fe, and 60 mug vitamin A/g salt
Trial: 7930242
Drug: Abbreviated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abbreviated heparin therapy (n = 118)
Trial: 7930242
Drug: 24-hour heparin
RxNorm normalized name: Heparine
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24-hour heparin therapy (n = 120)
Trial: 26293196
Drug: Preintervention preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preintervention preparation (reading a training manual and demonstration on a teddy bear)
Trial: 26293196
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preintervention preparation)
Trial: 22110268
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation with Peg-IFN-α 2b plus ribavirin
Trial: 19396424
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard insulin pump regimen)
Trial: 16793944
Drug: Oral ethinyl
RxNorm normalized name: ethinyl estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ethinyl estradiol (or-EE) 100 microg/day
Trial: 16793944
Drug: Testosterone 250
RxNorm normalized name: testosterone 250 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone 250 mg twice a week
Trial: 16793944
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (CA) 100 mg/day
Trial: 16793944
Drug: Transdermal 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta-estradiol (td-E) 100 microg twice a week
Trial: 14666945
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1 g per day vitamin C plus placebo)
Trial: 14666945
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C and E (1 g per day vitamin C plus 200 IU per kg vitamin E)
Trial: 8557013
Drug: Rocuronium (0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (0.45 mg kg‐1)
Trial: 8557013
Drug: Atracurium (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.35 mg kg‐1)
Trial: 8557013
Drug: Vecuronium (0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.075 mg kg‐1)
Trial: 6752961
Drug: ONO 802
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO 802 vaginal suppository (1.0 mg)
Trial: 31210499
Drug: Polarity therapy
RxNorm normalized name: Adlarity
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polarity therapy (4 sessions)
Trial: 26852833
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium (two 50‐mg tablets) and 2% lidocaine gel (3 mL applied on anterior cervical lip and cotton swab soaked in 2% lidocaine gel in cervical canal)
Trial: 26852833
Drug: Placebo (tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablets and gel)
Trial: 10609971
Drug: 15‐mg nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15‐mg nicotine patch plus behavioral treatment
Trial: 10609971
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch plus behavioral treatment
Trial: 7547655
Drug: Bupivacaine-epinephrine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine-epinephrine (5 micrograms/mL)
Trial: 1683191
Drug: Astemizole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole (10 mg daily)
Trial: 1683191
Drug: Hydroxyzine hydrochloride
RxNorm normalized name: hydroxyzine hydrochloride
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyzine hydrochloride (25 mg t.i.d.)
Trial: 1683191
Drug: Diphenhydramine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (25 mg t.i.d.)
Trial: 7185513
Drug: Ethambutol hydrochloride
RxNorm normalized name: Ethambutol Hydrochloride
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethambutol hydrochloride tablets (15 mg/kg dosage)
Trial: 30900297
Drug: Rectal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal fluid administration (plain water)
Trial: 30900297
Drug: Intravenous fluid
RxNorm normalized name: Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluid administration
Trial: 30900297
Drug: Nasogastric fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasogastric fluid administration
Trial: 30900297
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment, water and feed withheld)
Trial: 27518488
Drug: Flurbiprofen Axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen Axetil (1.0 mg/kg) before anesthesia induction (Group F1)
Trial: 24592974
Drug: Double death
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double death prime (combination of subliminal and supraliminal primes)
Trial: 22521201
Drug: Customized twice‐daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customized twice‐daily text messages
Trial: 15692469
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1% (twice daily at first signs or symptoms until clearance for 2 years)
Trial: 15692469
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1% (used only in the second year)
Trial: 10022424
Drug: Estrogen supplementation
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen supplementation (estradiol valerate, 2 mg daily; n = 7)
Trial: 1424269
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 13‐cis‐retinoic acid (0.1% cream)
Trial: 3933601
Drug: L-5HTP
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5HTP
Trial: 31330811
Drug: Best magnesium
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best magnesium formulation
Trial: 31330811
Drug: Worst magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Worst magnesium formulation
Trial: 28111929
Drug: CDFR0209 (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDFR0209 (omeprazole 40 mg + sodium bicarbonate 1100 mg)
Trial: 28111929
Drug: Delayed-release omeprazole
RxNorm normalized name: omeprazole Delayed Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release omeprazole (omeprazole-DR, Losec 40 mg)
Trial: 18289655
Drug: Physical Activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Activity (PA) of varying doses (frequency, intensity, duration)
Trial: 10892694
Drug: Pulsatile hypertonic
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile hypertonic saline nasal irrigation using a Water Pik device, twice daily for 3 to 6 weeks.
Trial: 9534937
Drug: LOW plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOW plasma volume expansion (14% using 6% dextran solution)
Trial: 9534937
Drug: HIGH plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIGH plasma volume expansion (21% using 6% dextran solution)
Trial: 7961010
Drug: Concurrent cis-platinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent cis-platinum and radiation (20 mg/m2 continuous infusion over 24 hours on days 1-4 and 22-25 of radiation schedule)
Trial: 7961010
Drug: Concurrent cis-platinum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent cis-platinum and radiation
Trial: 31960896
Drug: Volux injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volux injectable gel
Trial: 27404053
Drug: MPFF 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPFF 1000 mg
Trial: 16052316
Drug: Ondansetron monotherapy
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron monotherapy
Trial: 10642806
Drug: Budesonide 9
RxNorm normalized name: budesonide 9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 9 mg/day divided into three doses
Trial: 9032894
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml (2 micrograms) of recombinant hepatitis B vaccine
Trial: 9032894
Drug: 1.0 ml
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml (20 micrograms) of recombinant hepatitis B vaccine